0.53
price up icon7.72%   0.038
after-market Handel nachbörslich: .54 0.01 +1.89%
loading
Schlusskurs vom Vortag:
$0.492
Offen:
$0.49
24-Stunden-Volumen:
6.28M
Relative Volume:
0.95
Marktkapitalisierung:
$114.11M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.7067
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
+13.98%
1M Leistung:
-13.40%
6M Leistung:
-73.63%
1J Leistung:
-10.43%
1-Tages-Spanne:
Value
$0.49
$0.5583
1-Wochen-Bereich:
Value
$0.4501
$0.5583
52-Wochen-Spanne:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
Firmenname
Sangamo Therapeutics Inc
Name
Telefon
(510) 970-6000
Name
Adresse
501 CANAL BLVD., RICHMOND, CA
Name
Mitarbeiter
183
Name
Twitter
@sangamotx
Name
Nächster Verdiensttermin
2025-05-02
Name
Neueste SEC-Einreichungen
Name
SGMO's Discussions on Twitter

Vergleichen Sie SGMO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.53 114.11M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-13 Hochstufung Truist Hold → Buy
2024-12-10 Bestätigt H.C. Wainwright Buy
2023-11-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-04-28 Herabstufung BofA Securities Neutral → Underperform
2023-02-27 Hochstufung Wedbush Neutral → Outperform
2023-01-06 Herabstufung BofA Securities Buy → Neutral
2022-06-13 Fortgesetzt Wedbush Neutral
2021-05-04 Eingeleitet RBC Capital Mkts Outperform
2021-01-07 Fortgesetzt Guggenheim Neutral
2021-01-06 Eingeleitet Stifel Hold
2020-12-16 Fortgesetzt H.C. Wainwright Buy
2020-09-08 Eingeleitet BofA Securities Buy
2020-07-07 Eingeleitet SunTrust Buy
2019-08-26 Eingeleitet H.C. Wainwright Buy
2018-11-14 Herabstufung JP Morgan Overweight → Neutral
2018-11-09 Herabstufung Guggenheim Buy → Neutral
2018-10-10 Eingeleitet Guggenheim Buy
2018-06-20 Eingeleitet BofA/Merrill Buy
2017-11-15 Hochstufung Piper Jaffray Neutral → Overweight
2017-06-22 Fortgesetzt Jefferies Buy
2016-11-01 Herabstufung Wedbush Outperform → Neutral
2016-10-19 Herabstufung Piper Jaffray Overweight → Neutral
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-10-23 Fortgesetzt Jefferies Buy
2013-05-03 Eingeleitet BioLogic Equity Research Sell
2011-02-23 Bestätigt JMP Securities Mkt Outperform
2010-07-29 Bestätigt Wedbush Outperform
2009-10-19 Eingeleitet Brean Murray Sell
2009-10-07 Bestätigt Leerink Swann Outperform
2009-08-25 Bestätigt JMP Securities Mkt Outperform
Alle ansehen

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

pulisher
Jun 03, 2025

H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN

Jun 03, 2025
pulisher
Jun 01, 2025

10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 30, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

May 30, 2025
pulisher
May 29, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa

May 29, 2025
pulisher
May 27, 2025

Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com

May 27, 2025
pulisher
May 26, 2025

Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

May 26, 2025
pulisher
May 24, 2025

Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

May 24, 2025
pulisher
May 22, 2025

StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World

May 22, 2025
pulisher
May 16, 2025

Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World

May 16, 2025
pulisher
May 15, 2025

Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks

May 15, 2025
pulisher
May 14, 2025

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 14, 2025
pulisher
May 14, 2025

Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Sangamo Biosciences Announces $23 Million Share Offering - TipRanks

May 14, 2025
pulisher
May 14, 2025

Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics prices $23M securities offering - MSN

May 13, 2025
pulisher
May 13, 2025

Market Setbacks: Major Stocks Face Financial Hurdles - Finimize

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace

May 13, 2025
pulisher
May 13, 2025

Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 13, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 12, 2025
pulisher
May 12, 2025

Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | SGMO Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace

May 12, 2025
pulisher
May 12, 2025

Sangamo: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa

May 12, 2025
pulisher
May 12, 2025

Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus

May 12, 2025
pulisher
May 08, 2025

Sangamo hits milestone toward accelerated approval for ST-920 - Fabry Disease News

May 08, 2025
pulisher
May 07, 2025

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - BioSpace

May 07, 2025
pulisher
May 06, 2025

Sangamo Biosciences Receives Nasdaq Deficiency Notice - TipRanks

May 06, 2025

Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):